STX.L - Shield Therapeutics plc
| Previous close | 6.75 |
| Open | 6.74 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 6.60 - 6.90 |
| 52-week range | 5.52 - 15.00 |
| Volume | |
| Avg. volume | 2,097,338 |
| Market cap | 48.13M |
| Beta (5Y monthly) | 0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.17 |
| Earnings date | 06 Sept 2023 - 11 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 68.00 |
- EQS Group
Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions
Hardman & Co ResearchHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions 17-May-2023 / 07:15 GMT/BSTThe issuer is solely responsible for the content of this announcement.Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021,
- PR Newswire
Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc
Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc
- PR Newswire
Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc
Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc
Simply Wall St.Loss-Making Shield Therapeutics plc (LON:STX) Expected To Breakeven In The Medium-Term
Shield Therapeutics plc ( LON:STX ) is possibly approaching a major achievement in its business, so we would like to...
EQS GroupHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
Hardman & Co ResearchHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST Analyst interview | Life SciencesQ&A on Shield Therapeutics (STX) | Positioned for profitability with Viatris deal and its additional capitaltive Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews.Martin summarises a number of announcements made by the company recently, expl
- EQS Group
Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability
Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability 13-Jan-2023 / 07:15 GMT/BSTHardman & Co Research on Shield Therapeutics (STX): Positioned for growth and profitabilityShield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating
- Simply Wall St.
Shield Therapeutics plc's (LON:STX) Profit Outlook
Shield Therapeutics plc ( LON:STX ) is possibly approaching a major achievement in its business, so we would like to...
- Simply Wall St.
Shield Therapeutics (LON:STX) Is Risky Based On Its Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...